179 related articles for article (PubMed ID: 38254162)
1. A novel lipid metabolism-based risk model associated with immunosuppressive mechanisms in diffuse large B-cell lymphoma.
Zhang Z; Zhao C; Yang S; Lu W; Shi J
Lipids Health Dis; 2024 Jan; 23(1):20. PubMed ID: 38254162
[TBL] [Abstract][Full Text] [Related]
2. Identification of molecular subtypes and a novel prognostic model of diffuse large B-cell lymphoma based on a metabolism-associated gene signature.
He J; Chen Z; Xue Q; Sun P; Wang Y; Zhu C; Shi W
J Transl Med; 2022 Apr; 20(1):186. PubMed ID: 35468826
[TBL] [Abstract][Full Text] [Related]
3. Identifying
Xiang X; Gao LM; Zhang Y; Zhu Q; Zhao S; Liu W; Ye Y; Tang Y; Zhang W
PeerJ; 2023; 11():e16618. PubMed ID: 38099311
[TBL] [Abstract][Full Text] [Related]
4. CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma
Lou X; Zhao K; Xu J; Shuai L; Niu H; Cao Z; Wang J; Zhang Y
Front Immunol; 2022; 13():950213. PubMed ID: 36072582
[TBL] [Abstract][Full Text] [Related]
5. International Prognostic Index-Based Immune Prognostic Model for Diffuse Large B-Cell Lymphoma.
Mu S; Shi D; Ai L; Fan F; Peng F; Sun C; Hu Y
Front Immunol; 2021; 12():732006. PubMed ID: 34745101
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of the prognostic implication and immune infiltration of CISD2 in diffuse large B-cell lymphoma.
Zhang C; Lin Q; Li C; Qiu Y; Chen J; Zhu X
Front Immunol; 2023; 14():1277695. PubMed ID: 38155967
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of USP18 reduces tumor-infiltrating activated dendritic cells in extranodal diffuse large B cell lymphoma patients.
Zhao C; Huang R; Zeng Z; Yang S; Lu W; Liu J; Wei Y; Guo H; Zhang Y; Yan P; Huang Z; Shi J
Aging (Albany NY); 2021 May; 13(10):14131-14158. PubMed ID: 34001679
[TBL] [Abstract][Full Text] [Related]
8. Identification and Validation of a DNA Damage Repair-Related Signature for Diffuse Large B-Cell Lymphoma.
Li Y; Liu X; Chang Y; Fan B; Shangguan C; Chen H; Zhang L
Biomed Res Int; 2022; 2022():2645090. PubMed ID: 36281462
[TBL] [Abstract][Full Text] [Related]
9. Identification and Development of a 4-Gene Ferroptosis Signature Predicting Overall Survival for Diffuse Large B-Cell Lymphoma.
Wu H; Zhang J; Fu L; Wu R; Gu Z; Yin C; He K
Technol Cancer Res Treat; 2023; 22():15330338221147772. PubMed ID: 36762399
[No Abstract] [Full Text] [Related]
10. A glycolysis-related gene signatures in diffuse large B-Cell lymphoma predicts prognosis and tumor immune microenvironment.
Cui Y; Leng C
Front Cell Dev Biol; 2023; 11():1070777. PubMed ID: 36755971
[No Abstract] [Full Text] [Related]
11.
Sun J; Zhu X; Zhao Y; Zhou Q; Qi R; Liu H
Pharmgenomics Pers Med; 2021; 14():397-408. PubMed ID: 33833551
[TBL] [Abstract][Full Text] [Related]
12. Prediction significance of autophagy-related genes in survival probability and drug resistance in diffuse large B-cell lymphoma.
Xiong D; Wei X; Huang W; Zheng J; Feng R
Aging (Albany NY); 2024 Jan; 16(2):1049-1076. PubMed ID: 38240686
[TBL] [Abstract][Full Text] [Related]
13. [Screening of Differential Expression Autophagy Genes Related to the Prognosis of Diffuse Large B-Cell Lymphoma and Establishment of an Autophagy Model].
Zhang JD; Zhang HM; Lu D; Wang ZN; Chen HR; Lu XC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1101-1108. PubMed ID: 35981368
[TBL] [Abstract][Full Text] [Related]
14. A novel telomere-related genes model for predicting prognosis and treatment responsiveness in diffuse large B-cell lymphoma.
Zhao Z; Shen X; Zhao S; Wang J; Tian Y; Wang X; Tang B
Aging (Albany NY); 2023 Nov; 15(22):12927-12951. PubMed ID: 37976136
[TBL] [Abstract][Full Text] [Related]
15. Ferroptosis Markers Predict the Survival, Immune Infiltration, and Ibrutinib Resistance of Diffuse Large B cell Lymphoma.
Weng J; Chen L; Liu H; Yang XP; Huang L
Inflammation; 2022 Jun; 45(3):1146-1161. PubMed ID: 35064379
[TBL] [Abstract][Full Text] [Related]
16. Identification of Aging-Related Genes Associated with Prognostic Value and Immune Microenvironment Characteristics in Diffuse Large B-Cell Lymphoma.
Luo C; Nie H; Yu L
Oxid Med Cell Longev; 2022; 2022():3334522. PubMed ID: 35069971
[TBL] [Abstract][Full Text] [Related]
17. Identification and Validation of a Prognostic Prediction Model in Diffuse Large B-Cell Lymphoma.
Yan J; Yuan W; Zhang J; Li L; Zhang L; Zhang X; Zhang M
Front Endocrinol (Lausanne); 2022; 13():846357. PubMed ID: 35498426
[TBL] [Abstract][Full Text] [Related]
18. Identification and Assessment of Necroptosis-Related Genes in Clinical Prognosis and Immune Cells in Diffuse Large B-Cell Lymphoma.
Zhang Q; Zhu Z; Guan J; Zheng C
Front Oncol; 2022; 12():904614. PubMed ID: 35814424
[TBL] [Abstract][Full Text] [Related]
19. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
[TBL] [Abstract][Full Text] [Related]
20. A novel angiogenesis-related scoring model predicts prognosis risk and treatment responsiveness in diffuse large B-cell lymphoma.
Liu Y; Wang J; Shen X; Li L; Zhang N; Wang X; Tang B
Clin Exp Med; 2023 Nov; 23(7):3781-3797. PubMed ID: 37402040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]